Trial Profile

A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary)
Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
Focus Therapeutic Use
Sponsors Eli Lilly and Company

15 Jun 2025 Planned primary completion date changed from 1 Jul 2027 to 1 Nov 2027.
22 Nov 2024 Status changed from not yet recruiting to recruiting.
09 Oct 2024 Planned initiation date changed from 1 Sep 2024 to 28 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com